Daniel Lochner Buys Shares of Tectonic Therapeutic, Inc. $TECX

Key Points

  • Daniel Lochner bought 7,500 shares of Tectonic Therapeutic, Inc. ($TECX).
  • $TECX last traded around $30.28.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Daniel Lochner, Chief Financial Officer at Tectonic Therapeutic, Inc. ($TECX), bought 7,500 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Tectonic Therapeutic, Inc. Stock Down 15.0%

Shares of Tectonic Therapeutic, Inc. ($TECX) traded around $30.28 on Saturday, down 15.0% for the day.

Last price$30.28
Market cap$585.31M
Forward P/E-6.40
Beta0.22
52-week low$14.39
52-week high$39.53
50-day MA$33
200-day MA$27.11
Current ratio22.29
Quick ratio21.90
Debt-to-equity0.02

Tectonic Therapeutic, Inc. Earnings

EPS (ttm)-$4.57
Revenue (ttm)
Net margin0%
Return on equity-33.80%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$77.56
High target$93
Low target$60
Analysts covering9

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

ExchangeNasdaqGM
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
CEODr. Alise S. Reicin M.D., Ph.D.
Employees60

Get Tectonic Therapeutic, Inc. alerts

New 13F filings, insider trades, and analyst moves on $TECX, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.